Search Within

Viktoriya Paroder

  1. "Center for Molecular Imaging and Biotechnology (CMIB)"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (6)
Groups
  1. Body Imaging Service (14)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (14)
  3. GSK Faculty (14)
  4. Radiology, Department of (14)
  5. Department of Medicine (13)
  6. Gastrointestinal Oncology Service (13)

More Groups

People
  1. Yelena Janjigian (9)
  2. Steven Maron (8)
  3. Joanne Chou (7)
  4. Marinela Capanu (7)
  5. Neeta Pandit-Taskar (7)
  6. Geoffrey Ku (6)

More People

Years
  1. 2024 (2)
  2. 2023 (4)
  3. 2022 (3)
  4. 2021 (3)
  5. 2020 (2)
Publications
  1. Journal of Clinical Oncology (4)
  2. Journal of Nuclear Medicine (2)
  3. Annals of Oncology (1)
  4. Clinical Cancer Research (1)
  5. Clinical Colorectal Cancer (1)
  6. Journal of Gastrointestinal Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (4)
  2. Society of Nuclear Medicine (2)
  3. AME Publishing Company (1)
  4. American Association for Cancer Research (1)
  5. American Association of Physicists in Medicine (1)
  6. Cell Press (1)

More Publishers

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using (18)F-BMS-986229 PET
    Meeting Abstract

    Cytryn, S. L.; Pandit-Taskar, N.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Feder, L.; Philemond, S.; Lyashchenko, S. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • (18)F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer
    Journal Article

    Cytryn, S. L.; Pandit-Taskar, N.; Lumish, M. A.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Antoine, A.; Loegel, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: A case report
    Journal Article

    Kudelka, M. R.; Abou-Alfa, G. K.; O’Reilly, E. M.; Foote, M. B.; Sirohi, B.; Elias, R.; Shamseddine, A.; Paroder, V.; Moussa, A. M.; Cohen, P.; more...
    Journal of Gastrointestinal Oncology (2023)

    Fulltext@MSK | Save
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: A pilot study
    Journal Article

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Chou, J. F.; Capanu, M.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Lyashchenko, S. K.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer
    Meeting Abstract

    Cytryn, S.; Lumish, M.; Paroder, V.; Philemond, S.; Lewis, J.; Lyashchenko, S.; Janjigian, Y.; Pandit-Taskar, N.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Automated segmentation of adnexal ovarian metastases using joint distribution Wasserstein distance loss metric
    Meeting Abstract

    Nazib, A.; Boehm, K.; Paroder, V.; Shah, S.; Lakhman, Y.; Veeraraghavan, H.
    Medical Physics (2022)

    Fulltext@MSK | Save
  • ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
    Journal Article

    Su, W.; Mukherjee, R.; Yaeger, R.; Son, J.; Xu, J.; Na, N.; Timaul, N. M.; Hechtman, J.; Paroder, V.; Lin, M.; more...
    Molecular Cell (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save